Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.66 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14136257 | 0.94 | HSP90AB1 (0.64) | HSP90AB1HSP90AA1HSP90B1TRAP1CYP2C9 | |
| SCHEMBL4566934 | 0.90 | HSP90AB1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1CYP2C9 | |
| SCHEMBL421219 | 0.87 | HSP90AA1 (0.48) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL14367963 | 0.84 | HSP90AB1 (0.58) | HSP90AB1HSP90AA1HSP90B1TRAP1CYP2C9 | |
| SCHEMBL4566938 | 0.82 | HSP90AB1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1CYP2C9 | |
| SCHEMBL4566941 | 0.81 | HSP90AB1 (0.62) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL419884 | 0.80 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL29357308 | 0.80 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566968 | 0.79 | HSP90AB1 (0.61) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566944 | 0.79 | HSP90AB1 (0.69) | HSP90AB1HSP90AA1HSP90B1TRAP1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
| US-9439899-B2 | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439899-B2 | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9402831-B2 | Combination therapy of HSP90 inhibitors with BRAF inhibitors | SYNTA PHARMACEUTICAL CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9402831-B2 | Combination therapy of HSP90 inhibitors with BRAF inhibitors | SYNTA PHARMACEUTICAL CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP (US) | 2016-05-05 | — | — | US | disclosed |
| WO-2012037072-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2011149824-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011146803-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011133521-A2 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133520-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-08-11 | — | — | US | disclosed |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-08-11 | — | — | US | disclosed |
| WO-2011049946-A1 | COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | EGFR, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885HSP90B1 4/4885 |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.